The molecular events that drive Hepatitis B virus (HBV)-mediated transformation and tumorigenesis have remained largely unclear, due to the absence of a relevant primary model system.
Persistent HBV infection is the leading cause of chronic liver cirrhosis and hepatocellular carcinoma (HCC) world-wide 1, 2 . A combination of viral and host factors determines whether an individual infected with HBV will be able to clear the infection or will become a chronic carrier. Characterized by its high-host-species and organ-specificity, HBV infection and replication is thought to orchestrate an interplay between the immune system and viral-specific factors that eventually lead to the onset of HCC. Insights into the molecular mechanisms underlying HBV-induced HCC have largely been provided by epidemiological studies 3, 4 and genome wide analysis of viral and host characteristics [5] [6] [7] [8] [9] [10] , as well as by studies performed in in vitro settings using hepatoma cell lines 11, 12 .
However, a major deficiency attributed to the strict viral host and cell type tropism is the limited availability of relevant animal or in vitro model systems. chimpanzees remain the only animal model that supports the full HBV replication cycle, while available hepatoma cell line models are unsuitable for delineating the molecular steps towards tumorigenesis as they differ substantially from primary cells in their already tumor-derived gene expression profiles. Primary hepatocytes present the gold standard model system for HBV research in vitro. However they are difficult to obtain and rapidly lose their phenotype when cultured. More recently reports describe induced pluripotent stem cell (iPSC)derived hepatocytes, which are susceptible to HBV infection and support replication, providing a useful tool for studying host-virus determinants of replication [13] [14] [15] . However, limitations in the half-life and spread of this replicating culture system together with its long differentiation processes is limiting. As a consequence of deficiencies in available model systems, despite its fascinating biology, many questions regarding the life cycle of HBV, its mechanisms of persistence, and the HBV-induced molecular events underlying tumorigenesis remain largely unexplored in primary settings, and key viral and host players involved remain unknown.
The dependence of liver hepatocytes on spatial and matrix-derived signals [16] [17] [18] and their limited halflife in traditional cell culture has limited the development of primary HBV replication platforms suitable for drug screening. Recently, we have established a novel primary liver culture system based on isolation and expansion of primary cells that allows for the long-term expansion of liver cells as so called organoids 19, 20 . Liver organoids retain the ability to differentiate when cultured in media containing specific growth factors, and display the characteristics of differentiated hepatocytes 20 , thereby representing a primary in vitro cell culture platform for the molecular and mechanistic examination of liver disease and tumorigenesis 21 .
Results

HBV infected patient-derived liver organoids display an early cancer gene expression signature
We exploited the procedure for isolation and establishment of healthy liver organoid cultures 20 to establish the first primary culture system from HBV infected patients undergoing liver transplantation ( Fig. 1a ). In the latter, the explant is characterized by HBV-induced chronically cirrhotic liver tissue.
We established organoid cultures starting from cirrhotic tissue obtained from eleven explanted HBV infected livers (Table S1, Fig. 1a and b) and a biopsy obtained from an HBV-infected but cleared donor whose liver was functional and eligible for transplantation (Table S1 , iP-B). We generated and expanded organoid cultures from fresh and frozen explant tissue from all donors with similar efficiency.
Non-tumor, HBV-infected, patient-derived (iP) organoids were expanded in culture (EM) and displayed proliferation rates ( Fig. 1b and data not shown) and expression of progenitor markers LGR5, KRT7, HNF4α, and Sox9 (Fig. 1c ) comparable to that of healthy donor (hD) organoids. When grown in differentiation medium (DM), in which proliferation signals are removed and the progenitor fate is inhibited, liver organoid cultures acquire hepatocyte fate and differentiate into functional hepatocytes in vitro 20 . In DM, iP liver organoid cultures, as we have shown in hD liver organoid cultures 20 showed increased expression of hepatocyte-specific genes Albumin and Cytochrome C3A4 , and the recently identified cellular receptor for HBV hepatocyte entry Sodium taurocholate co-transporting polypeptide (NTCP), concomitant with decreased expression of the stem cell-specific gene LGR5 ( Fig. 1d and Supplementary Fig. 1 ). None of the iP organoids showed signs of HBV production at the RNA, DNA or protein level (data not shown), suggesting that liver progenitors do not support HBV replication. At the phenotypic level, while EM organoids grew larger in size and were translucent, differentiated iP organoids showed hepatocyte morphology and a thickening of the outer cell layer, comparable to hD organoids ( Fig. 1e and Supplementary Fig. 1 ) and produced comparable levels of albumin as detected by immunofluorescence staining ( Fig. 1e and Supplementary Fig. 1 ). Thus, non-tumor HBV iP and hD organoids display comparable phenotypes and capacity for differentiation.
To further characterize iP organoids, we performed mRNA sequencing of the organoid lines derived from HBV iP and compared their gene expression profile to that of hD organoids. We performed hierarchical clustering of protein-coding differentially expressed genes obtained from the comparison between organoids of five hD organoid lines with five iPs (iPs -BC and -BCC1-4) (Fig 1f) . The iP organoid lines were seeded from five HBV mono-infected patients with cirrhotic liver, four of which presented with small tumors at the time of explant) ( Fig 1F, Table S1 ). This comparison resulted in identification of an iP-characteristic "gene signature" ( Fig. 1f and Supplementary Table S2 ).
The early detection of HBV-related HCC is a challenge that remains critical to direct optimal clinical management of the disease. The presence of diagnostic biomarkers for early events in liver cell tumorigenesis would therefore be invaluable to early detection. In order to identify potential early biomarker genes for HBV-induced HCC, we ranked the differentially expressed genes according to the relative distance of their expression in hD versus HBV-iP derived organoids and identified a group of 33 putative early biomarker genes ( Fig. 2a ). Among these, CCNA1, STMN2, , which we found were upregulated in the non-tumor patient-derived organoids, were previously identified to be upregulated in HCC [22] [23] [24] [25] . Conversely, WNK2, RUSC2, CYP3A4 and RGN, among the significantly downregulated genes in the non-tumor iP organoids have been described as tumor suppressors downregulated in HCC 22, [26] [27] [28] .
GO-term and KEGG-pathway analysis revealed that the "early signature" genes were enriched in metabolic pathway-associated genes (Table S3 ). Importantly, this signature, when applied to all iP and hD samples, perfectly groups the healthy (grey) against the HBV-infected samples (black) (Fig. 2b ). In addition, the early signature groups the HBV-infected iP organoids (purple) and the HBV/HDV coinfected iP organoids closely together (light blue). The signature also separates the non-infected samples (green) and groups the iP organoids derived from patients who had HCC (red) as well as those derived from patients with acute liver failure (dark blue). Interestingly, iP-B and iP-BC, which are organoids derived from HBV-infected patients not displaying HCC, cluster together and closely to the larger group of iP organoids derived from patients with HCC (iP-BCC1-4). Notably, iP-B, derived from a liver clear of HBV infection at the time of donation, is the less similar in the group, yet still clustered with the HCC patients but away from the acute liver failure patient organoids, as indicated by the dendrogram branch to which iP-B belongs (Fig. 2b ). In agreement, multidimensional scaling analysis of all iP and hD samples indicates that all hD organoids are clearly separated from the rest and tightly grouped together, while the iP organoids form separate groups. We have therefore identified a specific gene signature/group which discriminates the hD and iP organoids among more complex classifications ( Fig. 2c ). Finally, the signature separates the TCGA LIHC samples from non-HCC tissue, when mapped onto the relevant TCGA gene expression data ( Fig. 2d ). Our data demonstrates that HBV iP-derived liver organoids are a primary cell culture model that resembles its diseased tissue of origin. Importantly, the model identified a novel early liver cancer gene signature in non-tumor HBV-infected patient-derived liver organoids, despite the absence of phenotypic signs of aberrant growth.
Human liver organoids allow modelling of HBV infection in vitro
To establish a defined in vitro primary model system for HBV infection and tumorigenesis, we infected hD liver organoids with HBV. Organoids were grown in either EM or DM for 7 days prior to infection with HBV or heat inactivated HBV (HI) ( Fig. 3a-b ). HBV infection and replication were determined by quantifying the levels of HBV DNA in the supernatant and examining the presence of HBV RNA and HBV specific proteins in infected cells. HBV DNA was detected in organoid culture supernatants from four days post infection indicating the presence of viral replication (Fig. 3b ). NTCP, the cellular receptor for HBV hepatocyte entry, was strongly upregulated during differentiation while detectable at low levels in EM organoids ( Supplementary Fig. 2 ). Accordingly, differentiated organoids maintained in DM were more efficiently infected and produced higher viral titers ( Fig. 3b -c). The RNA intermediates necessary for protein production and viral replication (HBV pol and Hbx) were present in infected organoids and detected by RT-PCR analysis ( Fig. 3c and 3e ). Furthermore, immunostaining using antibodies recognizing the HBV core (HBcAg) confirmed the presence of foci of HBV replication in the cultures (Fig. 3d ). Viral DNA, RNA and HBcAg were detected both in EM and DM (differentiated) organoid cultures. However, consistent with the higher levels of NTCP expression, levels of HBV replication were higher in differentiated organoids. Furthermore, infection of organoids with recombinant HepG2.2.15 virus resulted in production of cccDNA. Inoculum that lacks cccDNA was used as a negative control for the PCR and HBV plasmid DNA was used as a positive control ( Fig   3e and Supplementary Fig. 3a ). To determine whether the organoids are able to produce infectious virus, supernatants containing virus produced by organoids, which were infected with recombinant HepG2.2.15 HBV were collected, concentrated and used for spinoculation of hD organoids. As shown in Fig. 3f , infection of hD organoids with organoid-produced HBV resulted in expression of intracellular HBV RNA, indicating that organoids produce infectious viral particles.
Growth of viral isolates from patient material has been limited by the lack of an adequate primary model system. However, differentiated organoids were able to support infection and replication when challenged with HBV infected patient sera, as shown by production of viral DNA, expression of viral transcripts and positive immunostaining for HBsAg ( Fig. 3g and Supplementary Fig. 3b -c).This model system therefore provides a useful platform to investigate the role of specific viral factors in HBV infection. We next examined whether the ex vivo infected liver organoid platform would be amenable to drug screening according to the schematic in Fig. 3h . Infected organoids were treated with Tenofovir, a nucleoside reverse transcriptase inhibitor, which inhibits the reverse transcription of HBV pre-genomic RNA To DNA. HBV viral DNA production in the supernatant was inhibited by Tenofovir while as expected RNA levels remained the same (Fig. 3h ). Thus, ex vivo infected differentiated liver organoids provide a novel primary hepatocyte platform for drug screening.
In the organoids, HBV replication, infection and spread appear to be persistent until 8 days after infection when viral production drops significantly, likely because of the limited half-life of differentiated organoids in culture ( Fig. 4a ). If we stimulate the proliferation or recovery of the organoids by periodically culturing the organoids in EM, extending the half-life of the infected cultures, viral production is maintained for approximately one month post infection ( Supplementary   Fig. 4 ).
As an alternative approach to improve infection efficiency, we generated transgenic hD organoids exogenously expressing NTCP under expansion conditions ( Fig. 4b-d and Supplementary Fig. 5 ) via transduction of organoids with a lentiviral construct harboring the coding sequence of Flag-tagged NTCP ubiquitously expressed under a CMV promoter, followed by a blasticidin selection marker ( Fig.   4b ). Exogenous expression of NTCP in hepatoma cell lines was shown to confer susceptibility to infection 29 in line with our observed increased HBV infection in differentiated organoids, likely because of the higher level of NTCP expression. Immunofluorescence experiments performed on NTCP-liver organoids in expansion phase confirmed high levels of NTCP protein expression correctly localized to the cellular membrane ( Fig. 4d and Supplementary Fig. 5b ). Cholesterol target genes were induced in response to statin treatment in NTCP transgenic organoids, confirming the functionality of exogenously expressed NTCP ( Supplementary Fig. 5c ). However, when we then evaluated viral production after infection in NTCP organoid lines and compared it to that of the corresponding parental lines ( Fig. 4e ), HBV DNA and HBS antigen levels in the supernatant of NTCP-expressing organoids were similar to that of parental lines, suggesting that expression of NTCP alone is not sufficient to improve HBV infection rate in liver organoids grown in EM ( Fig. 4e-f and Supplementary Fig. 5d .
Differentiation of NTCP transgenic organoids led to higher levels of viral production in the supernatant ( Supplementary Fig. 5d ). This indicates that NTCP alone is not sufficient for HBV infection and additional factors may be necessary for optimal HBV infection of liver organoids.
To obtain a long-term, expandable, primary HBV producing liver organoid model system, we generated a lentiviral construct to produce transgenic organoid lines containing an integrated copy of HBV ( Fig. 4g-j and Supplementary Fig. 6 ). Interestingly, when the HBV genome was placed downstream of the CMV promoter, transgenic organoids, while efficiently expressing HBV RNA, did not support replication, as demonstrated by the low levels of HBV DNA in the culture supernatant ( Supplementary Fig. 6d ), pointing to CMV promoter-induced transcriptional interference with promoter usage required for mRNA transcription of individual HBV genes. Removal of the CMV promoter to generate "lenti-HBV" ( Supplementary Fig. 6e ) allowed for the generation of replicationcompetent, expandable, long term, hD transgenic lenti-HBV organoid lines, in which transcription from the HBV transgene results in protein and viral production ( Fig. 4j and Supplementary Fig. 6e -g).
Although lacking cccDNA, this model system provides a primary platform to screen for inhibitors of HBV gene expression.
Discussion
Here we present human liver organoids as a novel in vitro primary model system that supports HBV infection and replication, and which can be seeded from infected patients for molecular and functional analysis. Healthy donor liver organoids were efficiently infected with both recombinant virus as well as HBV infected patient serum, expressed HBS Ag and HBV core proteins, and produced HBV in the culture supernatant. The ex vivo infected organoid replication platform was amenable to screening for potential inhibitors of HBV replication, as we showed using the reverse transcriptase inhibitor Tenofovir. Thus the HBV infected organoid platform allows for the study of host and viral-specific factors that control the efficiency of HBV replication and viral production and provides a primary untransformed hepatocyte screening platform for discovery of candidate new drugs targeting HBV transcription and replication.
When cultured under differentiating growth conditions, the expression of the HBV receptor NTCP increased significantly in liver organoids. Consistent with the observed higher NTCP levels, in vitro infection of differentiated organoids with HBV led to higher levels of infection and replication. To mitigate the risk that long-term HBV replication would be limited by the half-life of differentiated (DM) liver organoid cultures, we generated transgenic organoids that exogenously expressed membrane localized NTCP under expansion conditions, to obtain long term HBV replicating cultures.
Surprisingly, the presence of NTCP did not result in more efficient infection of organoids, suggesting that although necessary, NTCP alone may not be sufficient for optimal infection. Consistent with our observations, HepG2 cell lines exogenously expressing NTCP, while susceptible to infection are inefficiently infected with HBV and require high viral titers 29, 30 . These observations are suggestive of the potential necessity for additional (co)receptors or downstream factors necessary for optimal infection in hepatocytes. In line with this notion, polyclonal lentivirally transduced liver organoids that contained integrated full length HBV genome, efficiently produced HBV under expansion conditions.
Recently alternative liver organoid model systems derived from human (induced) pluripotent stem cells [13] [14] [15] 31 as well as primary human hepatocyte coculture systems 32 have been developed that can be used to study hepatitis B virus infection. However, our liver organoids constitute a unique tool and innovative approach for the molecular characterization of patient-derived HBV-induced liver disease progression and HCC; the liver organoid platform combines the ability for long-term culturing, its amenability to molecular and genetic manipulation, with the possibility to achieve a phenotype corresponding to primary hepatocytes.
Early surveillance of the changes in gene expression or biomarkers that predict the occurrence of HCC is critical to enable patients to receive timely and successful treatment. Paving the way for personalized therapy of HBV infected patients, liver organoids can be seeded from infected patient liver biopsies or resection, at different stages of the disease. Our data demonstrates that HBV infected patient-derived liver organoids are a primary cell culture model that resembles its diseased tissue of origin. Comparison of the gene expression profiles of healthy donor to HBV-infected patient-derived liver organoids, and further HDV co-infected and acute liver failure patient sub-groups point to the extent to which organoids reflect the biology and represent the transcriptomic profiles of the primary non tumor tissue of origin. The identification of early aberrant gene regulatory networks and biomarkers that drive HBV-mediated HCC, detectable at an early non-tumor stage without phenotypic signs of tumorigenesis, allows for patient-specific surveillance of disease progression and provides a screening platform for candidate drugs that guide personalized treatment by targeting early stages in HBVmediated HCC.
Materials and Methods
Liver tissue: Liver organoids from healthy donors and HBV infected patients were isolated and cultured using the method previously described by Huch et al. 20 EM was changed twice a week, and cultures were split every 7-10 days according to organoid density.
For passaging (1:4-1:8, depending on growth rate of the culture), organoids were resuspended in 10ml Ad+++, incubated in ice for 10 minutes and collected by centrifugation (5 minutes at 200g).
Subsequently, organoids were incubated for 5 minutes in TrypLE Express at 37°C and mechanically disrupted by pipetting. After a further wash in Ad+++, cells were resuspended in BME solution and seeded in 24 or 48 wells suspension plates. After BME solution had solidified, wells were filled with 500µl (24 wells) or 250µl (48 wells) of human liver organoid expansion medium. Differentiation medium was changed twice a week for 7 days before infection or 10 days before staining for Albumin and HNF4α 20 .
Hepatic differentiation of liver organoids:
3' mRNA sequencing:
For each RNA preparation, 2 wells of organoids in expansion phase were collected in Trizol reagent (Sigma) 4-5 days after splitting. RNA was extracted according to manufacturer's instruction and resuspended in 30µl of nuclease free water. Total RNA was quantitated (ND1000 Spectrophotometer -PEQLAB). Samples were diluted accordingly to a mean concentration of approximately 100-150ng/μl and their quality assessed on a Bioanalyzer (Agilent Technologies) using the Agilent RNA 6000 Nano Kit reagents and protocol (Agilent Technologies). RNA samples were processed for library preparation using the 3' mRNA-Seq Library Prep Kit Protocol for Ion Torrent (QuantSeq-LEXOGEN™, Vienna, Austria), according to manufacturer's instructions. Briefly, up to 500ng from each RNA sample were used for first strand synthesis. The RNA was subsequently removed and 2nd strand synthesis was initiated by a random primer, containing Ion Torrent compatible linker sequences and appropriate in-line barcodes. 2nd strand synthesis was followed by magnetic bead-based purification and the resulting library was PCR-amplified for 14 cycles and re-purified.
Library quality and quantity was assessed on a Bioanalyzer using the DNA High Sensitivity Kit reagents and protocol (Agilent Technologies). The quantified libraries were pooled together at a final concentration of 100pM. The pools were templated and enriched on an Ion Proton One Touch system.
Templating was performed using the Ion PI™ Hi-Q™ OT2 200 Kit (Thermo Fisher Scientific), followed by sequencing using the Ion PI™ Hi-Q™ Sequencing 200 Kit on Ion Proton PI™ V2 chips (Thermo Fisher Scientific), an Ion Proton™ System, according to the manufacturer's instructions.
Short read mapping:
The Quant-Seq FASTQ files obtained from Ion Proton sequencing were mapped on the UCSC hg19 reference genome using a two-phase mapping procedure. Firstly, the short reads were mapped using tophat2 34 , with the following non-default settings: --read-mismatches 3 --read-gap- Gene expression levels were calculated using the 2ΔCt method, whereas fold increase was calculated using the 2ΔΔCt 41 . GAPDH was used as housekeeping control.
Immunofluorescence and image analysis: Human liver organoids were collected and washed three times to with cold Ad+++ to remove BME, then fixed with 4% paraformaldehyde for 30 and then seeded in BME following the culturing protocol. After BME solution has solidified, liver organoids were maintained in EM for 16h, washed 4 times with Ad+++ and cultured EM or DM as indicated. Detection of pol and HBX transcripts was performed using a previously published nested PCR protocol 42 .
Detection of HBV
Isolation and detection of HBV cccDNA from infected liver organoids: HBV cccDNA was isolated from HBV and HI (negative control) infected human liver organoids by a previously described alkali lysis plasmid DNA isolation protocol with a minor modification 43 
Data availability:
Sequencing data that support the findings of this study have been deposited in GEO with the accession code GSE 126798. 
